Introduction
3'-Azido-3'-deoxythymidine (AZT) has been shown to be effective for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) (Fischl et el., 1987) . However, the long-term clinical benefit of AZT appears to be limited, and patients often deteriorate during the second year of treatment. This coincides with the appearance in patients of virus variants showing resistance or reduced susceptibility to AZT cific mutations in the reverse transcriptase gene (Larder and Kemp 1989; Larder et al., 1991; Wahlberg et al., 1992) . Although the pathogenicity of AZT-resistant virus is not fully understood, these virus variants appear to revert relatively slowly if treatment is discontinued (Albert et sl., 1992) .
In addition to the development of resistance, the toxicity of AZT also causes clinical problems, and may necessitate a dose reduction or discontinuation in some patients . Thus, there is a need for alternative therapies for HIV-1 infection, and several drugs have been described as inhibitors of HIV-1 replication in vitro. Recently, 2', has been approved in the US for the treatment of HIV-infected patients.
In order to make informed clinical decisions concerning alternative treatment, information concerning the susceptibility of HIV-1 isolates and occurrence of cross-resistance is required. Therefore, primary isolates of HIV-1 from patients have been routinely tested to assess the natural variation in sensitivity to AZT, the development of AZT resistance and the occurrence of cross-resistance to alternative drugs. The results show that the development of resistance to AZT during therapy is fairly.common, and is associated with reduced susceptibility to ddl. Table 1 shows the sensitivity of the isolates to AZT, ddl, FLT, PFA and ddC. The IC so values for AZT ranged from <0.01 to 8.3 flM. Four of the isolates tested were from patients who had not received AZT. These isolates had IC so values of $ 0.05 flM (mean 0.02 flM), in accordance with previous data Richman et al., 1990) . Using an lC so of 0.05 flM as a cut-off, 20 isolates were sensitive to AZT, with a mean IC so ± SEM of 0.022 ± 0.004 flM. The remaining 28 isolates (58%) were resistant to AZT, with a mean IC so ± SEM of 1.13 ± 0.32 flM (P < 0.001 compared to mean IC so of AZT sensitive isolates; Mann Whitney).
Results

Sensitivity of primary isolates to antiviral drugs
The isolates varied in their sensitivity to ddl, with ICsos from 0.1 to 9.3 flM. The mean IC so ± SEM for ddl was 2.6 ± 0.41 flM. All the isolates were sensitive to FLT, the IC so in most cases being lower than the lowest concentration of drug tested (0.01611M). The mean IC 50 ± SEM for PFA there was a significant correlation (P= 0.006) between the was 29.7 ± 5.71LM (range 1-100 lLM), and for ddC 0.068 ± IC 50's for AZT and ddl. There was also a significant corre-0.0191LM (range < 0.01-0.51LM).
lation between the IC 50s for AZT and ddC ( ddl IGSO (J.LM) Fig. 1 . Correlation between the ICsos for AZT and ddl for the viral isolates described in Table 1 , including the line of best fit, determined by simple linear regression analysis (r= 0.428, P= 0.002).
IlM) it was 3.2 ± 0.591lM (P < 0.05, Mann Whitney). Comparisons were not drawn between FLT and other antiviral drugs since the majority of the ICsos for FLT were lower than the lowest concentration tested.
Correlation between resistance to Airand clinical factors ')'/ Table 1 shows the length of treatment with AZT, the CDC stage and the CD4 cell count for each of the patients from whom isolates were obtained. There was no correlation between the IC so for AZT and the length of treatment with AZT (Spearman coefficient 0.24, P= 0.1). The effect of CDC stage was not analysed since nearly all patients were stage IV.
Development of resistance to AZT in four patients
Four patients were followed during AZT treatment to assess the development of resistance (Table 2) . Before therapy, all four patients harboured virus that was sensitive to AZT, FLT, and PFA, but patients A and C harboured virus that was less sensitive to ddl than patients B and D. After 10 months therapy, the virus isolate from AZT sensitivity and cross-resistance in HIV-1 9 patient A was resistant to AZT (IC so =1.2 IlM), but there was no significant change in the sensitivity to the other drugs. Virus isolated from patients Band C was still sensitive to AZT after 19 and 16 months therapy, respectively. These two patients had previously been characterized as harbouring virus with one of the four mutations expected to be associated with AZT resistance . No significant change in the sensitivity to FLT or ddl was noted. Patient D developed virus increasingly resistant to AZT from 10 to 27 months. At the same time there was a decrease in the sensitivity of the virus to ddl.
Discussion
We examined the sensitivity to AZT, ddl, FLT, PFA, and ddC of primary isolates of HIV-1 from patients treated with AZT for various lengths of time. More than half of the isolates tested were resistant to AZT. The sensitivity of the isolates to ddl varied nearly 100-fold, and there was a significant correlation between the IC so for AZT and that for ddl. The AZT-resistant isolates were less susceptible to ddl than the AZT-sensitive isolates. For four AZT-resistant isolates (numbers 4819, 5011, 3843, and 3873) the IC so for ddl approached 10 IlM, although these patients had not been treated with ddl. There was also a significant correlation between the ICsos for AZT and ddC. Conversely, there was no correlation between the ICsos for AZT and for PFA, nor between those for ddl or ddC and PFA. Previous studies on individual isolates obtained by cultivation on cell lines showed cross-resistance between AZT and other anti-HIV drugs to be rare and mainly limited to other nucleosides containing a 3'-azido group (Larder et aI., 1990; Rooke et el., 1991; Gao et aI., 1992) . St. Clair et at. also showed recently that AZT-resistant isolates obtained by co-cultivation with PBMC from five different individuals were sensitive to ddl (St. Clair et sl., 1991) . We have studied primary HIV-1 isolates obtained from a large number of individuals, avoiding the use of established cell lines for isolation, passage or testing .. This gives a more comprehensive picture of the sensitivity to different antiviral drugs of clinical isolates from patients without restriction to the minority of isolates capable of growth in established cell lines. Furthermore, the measurement of antiviral sensitivity in vitro may be complicated by differences in the growth characteristics of different viral isolates (Boucher and Lange, 1992) . We performed a TCID so determination on the viral isolate in every case, and used a similar infectious dose of virus in all experiments. Thus, the diminished sensitivities of the AZT-resistant isolates to ddl and ddC are unlikely to result from a general increase in replicative capacity. This is also shown by the lack of any decrease in sensitivity to PFA of the AZT-resistant isolates. The acquisition of resistance to AZT has been shown to be associated with specific mutations in the reverse transcriptase gene (Larder and Kemp, 1989; Larder et el., 1989 Larder et el., , 1991 Boucher et aI., 1992b; Muckenthaler et st., 1992; . Resistance to ddl in patients treated with the drug was also shown to be associated with mutation (at codon 74) of the reverse transcriptase (St. Clair et el., 1991) . This mutation appeared to confer sensitivity to AZT despite the presence of mutations normally associated with AZT resistance (St. Clair et et., 1991) . Furthermore, Gu et at. have recently described a mutation at position 184 of the reverse transcriptase in in vitro-generated mutants which gave rise to resistance to ddl and also cross-resistance to ddC . However, these mutants remained sensitive to AZT and it appears that mutations in the reverse transcriptase giving rise to resistance to ddl can affect the sensitivity of the virus to other dideoxynucleosides. We intend to sequence several of the isolates described in this study, to determine whether specific mutations exist which may be associated with resistance to AZT and cross-resistance to ddl and ddC, and how these compare to previously described mutations.
The factors which determine the development of resistance are still unclear. Earlier studies suggested that resistance to AZT developed more readily in patients at more advanced stages of HIV disease (Richman et el., 1990) . In our study, the development of resistance was not associated with the length of treatment with AZT. Several patients treated with AZT for 2 or 3 years remained sensitive to AZT. Differences in the viral load and growth characteristics of a particular patient's isolate could affect the likelihood of resistance development (Boucher et aI., 1992a) , and we intend to investigate several of the isolates in this respect. A recent study of AZT-sensitivity in children treated with AZT also found no relation between length of treatment and development of resistance, although CD4 counts were significantly lower in those who developed resistance (Tudor-Williams et el., 1992) .
The clinical significance of development of resistance to AZT is still under investigation. The relatively slow reversion of the mutations associated with AZT-resistance upon cessation of therapy (Albert et el., 1992) argues for an unchanged replicative potential of AZTresistant virus compared to wild type. Recent results indicate a poorer prognosis for children harbouring AZTresistant virus (TUdor-Williams et el., 1992) . The growth characteristics of the viral isolate are also of importance, perhaps more so than the development of resistance per se (Boucher et a/., 1992a) . Also, Kahn et at. have shown recently a survival advantage amongst patients changing to ddl therapy compared to those continuing with AZT therapy (Kahn et aI., 1992) . Therefore, the availability and use of alternative antiretroviral therapy in patients harbouring AZT-resistant strains is of special importance. The reduced susceptibility to ddl and ddC of some AZTresistant isolates presented here has bearing upon the use of these drugs as an alternative therapy in cases of resistance to AZT.
Materials and Experimental procedures
Patients
Forty-eight HIV-1 seropositive individuals at various stages of diseasewho had been treated with AZT for various lengths of time were investigated. Viral isolations were performed to check for resistance to AZT and cross-resistance to other drugs. Patients did not receive ddl or other specific anti-HIV drugs. Six patients (numbers 3827, 3841, 3976, 4171, 5227, and 5466) received intermittent treatment with PFA for cytomegalovirus infection, and patients 3827, 3841, 3976, and 5466 also received ganciclovir (DHPG). Serial viral isolations were also performed on four additional patients (A-D) before and during AZT therapy to monitor the development of resistanceto AZT. During this period patients C and D were treated intermittently with PFA for cytomegalovirus infection. The reverse transcriptase gene was sequenced, and the development of mutations in these patients was the SUbject of a previous publication . Virus was also isolated from two of these patients (C and D) after cessation of longterm AZT therapy. These post-treatment isolates have also been sequenced previously for mutations associated with AZT resistance (Albertat el., 1992) .
Viral isolation
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque centrifugation. Primary isolates of HIV-1 were made by co-cultivation of patient PBMC with phytohaemagglutinin-stimulated PBMC from healthy seronegative donors in RPMI 1640 medium with 10% fetal calf serum, 5 units mr"
interleukin-2 (Amersham, Amersham, UK) and antibiotics (Albert and Fenyo, 1990) . Isolates were either used directly, or passaged once on blood donor PBMC, and were never cultivated in cell lines. Isolates were used fresh or frozen at -70°C for later use.
Antiviral sensitivity determination
Sensitivity of primary isolates was determined in PBMC in microtitre plates. 50000 PBMC were placed in each well with the virus isolate at two different dilutions, usually 1:20 and 1:100. Five five-fold dilutions of the drugs to be tested (AZT, ddl, 3'-fluoro-3'-deoxythymidine [FLT], phosphonoformate [PFA], or dideoxycytidine [ddC]) dissolved in medium were added. Four drugs were tested on the same occasion per microtitre plate. The highest concentration of drug tested was: AZT, FLT, and ddC, 10IlM; ddl. 100IlM; PFA, 1000IlM. All drugs used were a kind gift from Professor Bo Oberg, Medivir, Huddinge, Sweden. Each plate also contained four five-fold titrations of the virus to determine the 8)J%infective dose in tissue culture (TCID so). A TCID so of bet$'{.een 10-50 was used to evaluate drug sensitivity. The plates were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. On days 7 to 11, the growth of the virus controls was checked by HIV-1 specific antigen ELISA (Koshida et al., 1989; Sundqvist et al., 1989) . When appropriate viral growth had occurred, 20 III of lysis buffer (phosphate buffered saline with 0.5% bovine serum albumin, 0.05% Tween 20 and 5% Triton X100) were added to the plates. The resulting cell lysate was then tested in the HIV-1 ELISA. Control wells were first titrated and then diluted to give appropriate positive controls and minimum background. IC so values were calculated by comparison to viral growth in the absence of drugs.
Statistical analysis
Results were analysed for statistical significance using the Spearman rank correlation and Mann Whitney test, and simple linear reqresslon analysis.
